Biologics for the Management of Erythrodermic Psoriasis: An Updated Review

References

• Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi:10.1016/S0140-6736(20)32549-6
   PubMed Web of Science ®Google Scholar
• Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007;25(6):535–546. doi:10.1016/j.clindermatol.2007.08.007
   PubMed Web of Science ®Google Scholar
• Merola JF, Li T, Li WQ, Cho E, Qureshi AA. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41(5):486–489. doi:10.1111/ced.12805
   PubMed Web of Science ®Google Scholar
• Shao S, Wang G, Maverakis E, Gudjonsson JE. Targeted treatment for erythrodermic psoriasis: rationale and recent advances. Drugs. 2020;80(6):525–534. doi:10.1007/s40265-020-01283-2
   PubMed Web of Science ®Google Scholar
• Lo Y, Tsai TF. Updates on the treatment of erythrodermic psoriasis. Psoriasis. 2021;11:59–73. doi:10.2147/PTT.S288345
   PubMed Web of Science ®Google Scholar
• Yin L, Xu JL, Hu YY, Johnston A, Yin ZQ. Systemic abnormalities of psoriatic patients: a retrospective study. Clin Cosmet Investig Dermatol. 2016;9:443–449. doi:10.2147/CCID.S121302
   PubMedGoogle Scholar
• Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(4):655–662. doi:10.1016/j.jaad.2009.05.048
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Megna M. Paradoxical reactions to biologicals for psoriasis. Expert Opin Biol Ther. 2022;22(12):1435–1437. doi:10.1080/14712598.2022.2153593
   PubMed Web of Science ®Google Scholar
• Megna M, Ocampo-Garza SS, Potestio L, et al. New-onset psoriatic arthritis under biologics in psoriasis patients: an increasing challenge? Biomedicines. 2021;9(10):64. doi:10.3390/biomedicines9101482
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Camela E. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther. 2022;1–18. doi:10.1080/14712598.2022.2089020
   Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023:1–16. doi:10.1080/14740338.2023.2173171
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023:1–17. doi:10.1080/14740338.2023.2173170
   PubMed Web of Science ®Google Scholar
• Dogra S, Mehta H. Biological treatment for erythrodermic psoriasis. Expert Opin Biol Ther. 2022;22(12):1531–1543. doi:10.1080/14712598.2022.2128669
   PubMed Web of Science ®Google Scholar
• Carrasquillo OY, Pabón-Cartagena G, Falto-Aizpurua LA, et al. Treatment of erythrodermic psoriasis with biologics: a systematic review. J Am Acad Dermatol. 2020;83(1):151–158. doi:10.1016/j.jaad.2020.03.073
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023;1–16. doi:10.1080/13543784.2023.2219387
   PubMed Web of Science ®Google Scholar
• Richetta AG, Maiani E, Carlomagno V, et al. Treatment of erythrodermic psoriasis in HCV+ patient with Adalimumab. Dermatol Ther. 2009;22(Suppl 1):S16–8. doi:10.1111/j.1529-8019.2009.01266.x
   PubMedGoogle Scholar
• Wu H, Shen Y, Zhang L, et al. Erythrodermic Psoriasis in a Patient with Plaque Psoriasis Who Presented with Symptoms of Niacin Deficiency: a Special Case Report. Clin Cosmet Investig Dermatol. 2022;15:2097–2100. doi:10.2147/CCID.S378591
   PubMed Web of Science ®Google Scholar
• Mumoli N, Vitale J, Gambaccini L, Sabatini S, Brondi B, Cei M. Erythrodermic psoriasis. QJM. 2014;107(4):315. doi:10.1093/qjmed/hct139
   PubMed Web of Science ®Google Scholar
• Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol. 2006;155(1):156–159. doi:10.1111/j.1365-2133.2006.07217.x
   PubMed Web of Science ®Google Scholar
• Talat H, Wahid Z, Feroz F, Sajid M. Erythrodermic Psoriasis and Hepatitis C Infection Treated with Pegylated Interferon and Anti-TNFα α(Etanercept) Therapy. J Coll Physicians Surg Pak. 2017;27(9):S77–S79.
   PubMed Web of Science ®Google Scholar
• Fraga NA, Paim M, Follador I, Ramos AN. Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept. An Bras Dermatol. 2011;86(4 Suppl 1):S144–7. doi:10.1590/s0365-05962011000700038
   PubMed Web of Science ®Google Scholar
• Okubo Y, Umezawa Y, Sakurai S, Hoshii N. Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results. Dermatol Ther (Heidelb). 2022;12(6):1397–1415. doi:10.1007/s13555-022-00741-x
   PubMed Web of Science ®Google Scholar
• Takahashi MDF, Castro LGM, Romiti R. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol. 2007;157(4):828–831. doi:10.1111/j.1365-2133.2007.08111.x
   PubMed Web of Science ®Google Scholar
• Heikkilä H, Ranki A, Cajanus S, Karvonen SL. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis. Arch Dermatol. 2005;141(12):1607–1610. doi:10.1001/archderm.141.12.1607
   PubMedGoogle Scholar
• Kurokawa R, Hagiwara A, Niijima Y, Kojima K. Computed tomography imaging findings in erythrodermic psoriasis treated with infliximab: a case report. Radiol case rep. 2018;13(2):460–463. doi:10.1016/j.radcr.2018.02.005
   PubMedGoogle Scholar
• Trídico LA, Antonio JR, Mathias CE. Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis. An Bras Dermatol. 2017;92(5):743–745. doi:10.1590/abd1806-4841.20176565
   PubMed Web of Science ®Google Scholar
• Damiani G, Pacifico A, Russo F, et al. Use of Secukinumab in a Cohort of Erythrodermic Psoriatic Patients: a Pilot Study. J Clin Med. 2019;8:6. doi:10.3390/jcm8060770
   Web of Science ®Google Scholar
• Weng HJ, Wang TS, Tsai TF. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series. Br J Dermatol. 2018;178(6):1439–1440. doi:10.1111/bjd.16252
   PubMed Web of Science ®Google Scholar
• Mateu-Puchades A, Santos-Alarcón S, Martorell-Calatayud A, Pujol-Marco C, Sánchez-Carazo JL. Erythrodermic psoriasis and secukinumab: our clinical experience. Dermatol Ther. 2018;31(4):e12607. doi:10.1111/dth.12607
   PubMed Web of Science ®Google Scholar
• Panda M, Raj C, Panda AK, Debata I. Secukinumab in Erythrodermic Psoriasis: real World Experience of 6 Patients Successfully Treated by Injecting at Unconventional Sites. Indian J Dermatol. 2021;66(6):677–680. doi:10.4103/ijd.ijd_221_21
   PubMed Web of Science ®Google Scholar
• Mugheddu C, Atzori L, Lappi A, Pau M, Murgia S, Rongioletti F. Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2017;31(9):e420–e421. doi:10.1111/jdv.14234
   PubMed Web of Science ®Google Scholar
• Liu LC, Jin XH, Sun C, Xia JX. Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature. Dermatol Ther. 2021;34(2):e14825. doi:10.1111/dth.14825
   PubMed Web of Science ®Google Scholar
• Carriero M. Erythrodermic psoriasis and palmoplantar hyperkeratosis successfully treated with secukinumab: a case report. Drug Target Insights. 2022;16:1–5. doi:10.33393/dti.2022.2355
   PubMed Web of Science ®Google Scholar
• Lu J, Tang S, Yu N, Yi X, Li Y. Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report. J Int Med Res. 2020;48(11):300060520969494. doi:10.1177/0300060520969494
   PubMed Web of Science ®Google Scholar
• Pizzatti L, Mugheddu C, Sanna S, Atzori L, Rongioletti F. Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab. Dermatol Ther. 2020;33(3):e13348. doi:10.1111/dth.13348
   PubMed Web of Science ®Google Scholar
• Ozcan I, Karadag AS, Ceren E, Demirci B, Cebeci F. A case of erythrodermic psoriasis in which Adalimumab injection sites are preserved. Dermatol Ther. 2021;34(2):e14865. doi:10.1111/dth.14865
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zhang X, Wang R, Wang Y, Gong L, Li C. Vaccine-induced erythrodermic psoriasis in a child successfully treated with secukinumab: a case report and brief literature review. Dermatol Ther. 2022;35(9):e15684. doi:10.1111/dth.15684
   PubMed Web of Science ®Google Scholar
• Dogra S, Bishnoi A, Narang T, Handa S. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis. Dermatol Ther. 2018;31(4):e12611. doi:10.1111/dth.12611
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29(6):1148–1155. doi:10.1111/jdv.12773
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355–362. doi:10.1111/1346-8138.13622
   PubMed Web of Science ®Google Scholar
• Morita A, Okubo Y, Morisaki Y, Torisu-Itakura H. Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis. Dermatol Ther (Heidelb). 2022;12(2):481–494. doi:10.1007/s13555-021-00666-x
   PubMed Web of Science ®Google Scholar
• Lo Y, Tsai TF. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series. Br J Dermatol. 2019;181(5):1106–1107. doi:10.1111/bjd.18174
   PubMed Web of Science ®Google Scholar
• Trovato E, Orsini C, Russo F, Cortonesi G, Rubegni P. Ixekizumab as treatment of erythrodermic psoriasis. Dermatol Ther. 2021;34(2):e14868. doi:10.1111/dth.14868
   PubMed Web of Science ®Google Scholar
• Megna M, Gallo L, Balato N, Balato A. A case of erythrodermic psoriasis successfully treated with ixekizumab. Dermatol Ther. 2019;32(2):e12825. doi:10.1111/dth.12825
   PubMed Web of Science ®Google Scholar
• Vinaixa Aranzazu A, Morillas-Lahuerta V. Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient. Eur J Dermatol. 2021;31(4):564–565. doi:10.1684/ejd.2021.4087
   PubMed Web of Science ®Google Scholar
• Pinto-Pulido EL, Polo-Rodríguez I, González-Cañete M, García-Verdú E, Piteiro-Bermejo AB, Medina-Montalvo S. Ixekizumab treatment for drug-induced erythrodermic psoriasis. Dermatol Ther. 2022;35(11):e15863. doi:10.1111/dth.15863
   PubMed Web of Science ®Google Scholar
• Avallone G, Cariti C, Dapavo P, et al. Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2022;36(7):e574–e576. doi:10.1111/jdv.18069
   PubMed Web of Science ®Google Scholar
• Bernardini N, Skroza N, Proietti I, et al. Erythrodermic Psoriasis Successfully Treated with Anti IL-17: a Case Series. Acta Dermatovenerol Croat. 2021;29(4):191–195.
   PubMed Web of Science ®Google Scholar
• Pangilinan MCG, Sermswan P, Asawanonda P. Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis. Case Rep Dermatol. 2020;12(2):132–137. doi:10.1159/000508781
   PubMed Web of Science ®Google Scholar
• Mota F, Mendes-Bastos P. Erythrodermic Psoriasis Successfully Treated With Brodalumab: a Case Series. Actas Dermosifiliogr. 2023. doi:10.1016/j.ad.2022.10.048
   Google Scholar
• Megna M, Fabbrocini G, Ferrillo M, Cinelli E. Erythrodermic psoriasis successfully and rapidly treated with brodalumab: report of two cases. Dermatol Ther. 2020;33(6):e14351. doi:10.1111/dth.14351
   PubMed Web of Science ®Google Scholar
• Bernardini N, Skroza N, Tolino E, et al. Recurrent erythrodermic psoriasis and polycythemia successfully treated with brodalumab. Dermatol Ther. 2020;33(6):e14338. doi:10.1111/dth.14338
   PubMed Web of Science ®Google Scholar
• Megna M, Battista T, Potestio L, et al. A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab. J Cosmet Dermatol. 2023;22(3):1146–1148. doi:10.1111/jocd.15543
   PubMed Web of Science ®Google Scholar
• Pescitelli L, Dini V, Gisondi P, et al. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis. J Dermatol Sci. 2015;78(2):149–151. doi:10.1016/j.jdermsci.2015.01.005
   PubMed Web of Science ®Google Scholar
• Wang TS, Tsai TF. Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: a case series. J Dermatol. 2011;38(11):1096–1099. doi:10.1111/j.1346-8138.2011.01224.x
   PubMed Web of Science ®Google Scholar
• Stinco G, Piccirillo A, Errichetti E, Bergamo S, Patrone P. Treatment of recalcitrant erythrodermic psoriasis with ustekinumab. Eur J Dermatol. 2014;24(3):387–390. doi:10.1684/ejd.2014.2325
   PubMed Web of Science ®Google Scholar
• Santos-Juanes J, Coto-Segura P, Mas-Vidal A, Galache Osuna C. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol. 2010;162(5):1144–1146. doi:10.1111/j.1365-2133.2010.09669.x
   PubMed Web of Science ®Google Scholar
• Saraceno R, Talamonti M, Galluzzo M, Chiricozzi A, Costanzo A, Chimenti S. Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases. Case Rep Dermatol. 2013;5(3):254–259. doi:10.1159/000348645
   PubMedGoogle Scholar
• Kim YS, Kim HJ, Lee S, Park YL. Erythrodermic Psoriasis Improved by Ustekinumab: a Report of Two Cases. Ann Dermatol. 2016;28(1):121–122. doi:10.5021/ad.2016.28.1.121
   PubMed Web of Science ®Google Scholar
• Castiñeiras I, Fernández-Diaz L, Juárez Y, Lueiro M. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies. J Dermatol. 2012;39(8):730–731. doi:10.1111/j.1346-8138.2011.01499.x
   PubMed Web of Science ®Google Scholar
• Koutsoukou XA, Papadavid E, Theodoropoulos K, Rigopoulos D. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission. Dermatol Ther. 2014;27(5):257–259. doi:10.1111/dth.12131
   PubMed Web of Science ®Google Scholar
• Trevisan G, Germi L, Naldi L. Erythrodermic psoriasis improved by Tildrakizumab. Dermatology Rep. 2022;14(4):9448. doi:10.4081/dr.2022.9448
   PubMedGoogle Scholar
• Megna M, Potestio L, Fabbrocini G, Cinelli E. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;e15030. doi:10.1111/dth.15030
   PubMed Web of Science ®Google Scholar
• Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529–539. doi:10.1111/1346-8138.14294
   PubMed Web of Science ®Google Scholar
• Chiang CY, Tsai TF. Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab. Dermatol Ther (Heidelb). 2021;11(1):301–306. doi:10.1007/s13555-020-00480-x
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Camela E, Fabbrocini G, Marasca C. A case of erythrodermic psoriasis successfully treated with guselkumab. Dermatol Ther. 2020;33(2):e13238. doi:10.1111/dth.13238
   PubMed Web of Science ®Google Scholar
• Yamanaka K, Okubo Y, Yasuda I, Saito N, Messina I, Morita A. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study. J Dermatol. 2023;50(2):195–202. doi:10.1111/1346-8138.16667
   PubMed Web of Science ®Google Scholar
• Alajlan A, Madani A, Qadoumi TA, Aljaloud A, Alessa M. Erythrodermic Psoriasis Managed with Risankizumab. Case Rep Dermatol. 2022;14(2):219–224. doi:10.1159/000525774
   PubMed Web of Science ®Google Scholar
• Viguier M, Pagès C, Aubin F, et al. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol. 2012;167(2):417–423. doi:10.1111/j.1365-2133.2012.10940.x
   PubMed Web of Science ®Google Scholar
• Billi AC, Gudjonsson JE. Adalimumab in Psoriasis: how Much Is Enough? J Invest Dermatol. 2019;139(1):19–22. doi:10.1016/j.jid.2018.08.012
   PubMed Web of Science ®Google Scholar
• Megna M, Villani A, Potestio L, Camela E, Fabbrocini G, Ocampo-Garza SS. Adalimumab biosimilar in a pediatric patient: clinical and in vivo reflectance confocal microscopy evaluation. Dermatol Ther. 2022;35(9):e15679. doi:10.1111/dth.15679
   PubMed Web of Science ®Google Scholar
• Tichy M. Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following Adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab. Postep Dermatol i Alergol. 2019;36(4):495–497. doi:10.5114/ada.2019.87454
   PubMed Web of Science ®Google Scholar
• Benhadou F, Hellgren G, Willaert F, Del Marmol V. Acute Erythroderma in a Patient Receiving TNF-α-Blocking Therapy for Hidradenitis Suppurativa. Case Rep Dermatol. 2018;10(1):7–12. doi:10.1159/000485911
   PubMed Web of Science ®Google Scholar
• Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2012;67(5):e179–85. doi:10.1016/j.jaad.2011.05.038
   PubMed Web of Science ®Google Scholar
• Goiriz R, Daudén E, Pérez-Gala S, Guhl G, García-Díez A. Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin Exp Dermatol. 2007;32(2):176–179. doi:10.1111/j.1365-2230.2006.02315.x
   PubMed Web of Science ®Google Scholar
• Nowsheen S, Kohorst JJ, El-Azhary RA. Adalimumab-induced erythrodermic reactions. Int J Dermatol. 2019;58(10):e204–e206. doi:10.1111/ijd.14503
   PubMed Web of Science ®Google Scholar
• Kapoor DM, Tan KW. Erythrodermic psoriasis peculiarly sparing anti-TNF injection sites in a patient with secondary loss of efficacy. Dermatol Ther. 2017;30:6. doi:10.1111/dth.12551
   Web of Science ®Google Scholar
• Prinz JC, Puig L, Girolomoni G. Treatment of psoriasis with etanercept: the typical patient profile. J Eur Acad Dermatol Venereol. 2016;30(7):1092–1099. doi:10.1111/jdv.13662
   PubMed Web of Science ®Google Scholar
• Campanati A, Benfaremo D, Luchetti MM, Ganzetti G, Gabrielli A, Offidani A. Certolizumab pegol for the treatment of psoriasis. Expert Opin Biol Ther. 2017;17(3):387–394. doi:10.1080/14712598.2017.1283401
   PubMed Web of Science ®Google Scholar
• Subedi S, Gong Y, Chen Y, Shi Y. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events. Drug Des Devel Ther. 2019;13:2491–2502. doi:10.2147/DDDT.S200147
   PubMed Web of Science ®Google Scholar
• Bruzzese V, Pepe J. Efficacy of cyclosporine in the treatment of a case of infliximab-induced erythrodermic psoriasis. Int J Immunopathol Pharmacol. 2009;22(1):235–238. doi:10.1177/039463200902200126
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Camela E, Fabbrocini G, Ruggiero A. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;e15667. doi:10.1111/dth.15667
   PubMed Web of Science ®Google Scholar
• Martora F, Megna M, Battista T, et al. Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: a Review of the Real-Life Experience. Clin Cosmet Investig Dermatol. 2023;16:135–148. doi:10.2147/CCID.S391356
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Campione E, Mazzilli S, Bianchi L, Talamonti M. A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab. J Dermatolog Treat. 2018;1–11. doi:10.1080/09546634.2018.1524818
   PubMed Web of Science ®Google Scholar
• Marasca C, Fornaro L, Martora F, Picone V, Fabbrocini G, Megna M. Onset of vitiligo in a psoriasis patient on ixekizumab. Dermatol Ther. 2021;34(5):e15102. doi:10.1111/dth.15102
   PubMed Web of Science ®Google Scholar
• Potter KA, Motaparthi K, Schoch JJ. Erythrodermic psoriasis after discontinuation of ixekizumab. JAAD Case Rep. 2018;4(1):22–23. doi:10.1016/j.jdcr.2017.06.026
   PubMedGoogle Scholar
• Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M. Bimekizumab for the Treatment of Psoriasis: a Review of the Current Knowledge. Psoriasis. 2022;12:127–137. doi:10.2147/PTT.S367744
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Martora F, Villani A, Comune R, Megna M. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert Opin Drug Saf. 2023. doi:10.1080/14740338.2023.2218086
   Web of Science ®Google Scholar
• Valenti M, Gargiulo L, Ibba L, Pavia G, Narcisi A, Costanzo A. Sub-erythrodermic psoriasis successfully treated with bimekizumab: a case report. Dermatol Ther. 2022;35(12):e15952. doi:10.1111/dth.15952
   PubMed Web of Science ®Google Scholar
• Yiu ZZ, Warren RB. Ustekinumab for the treatment of psoriasis: an evidence update. Semin Cutan Med Surg. 2018;37(3):143–147. doi:10.12788/j.sder.2018.040
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Camela E, Potestio L, Fabbrocini G, Megna M. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022;21(12):1445–1451. doi:10.1080/14740338.2022.2160447
   PubMed Web of Science ®Google Scholar
• Potestio L, Piscitelli I, Fabbrocini G, Martora F, Ruggiero A. Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection. Clin Cosmet Investig Dermatol. 2023;16:369–373. doi:10.2147/CCID.S403294
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M. Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: results from 52 Weeks Real-Life Retrospective Study. Clin Cosmet Investig Dermatol. 2023;16:529–536. doi:10.2147/CCID.S402183
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941. doi:10.1111/dth.15941
   PubMed Web of Science ®Google Scholar
• Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022:1–8. doi:10.1080/09546634.2022.2081655
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatolog Treat. 2022;1–18. doi:10.1080/09546634.2022.2036674
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Ruggiero A. Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: a 3-Year Real-Life Retrospective Study. Psoriasis. 2022;12:205–212. doi:10.2147/PTT.S372262
   PubMed Web of Science ®Google Scholar
• Megna M, Marano L, Camela E, et al. A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab. Dermatol Ther. 2022;35(10):e15766. doi:10.1111/dth.15766
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: a Review of the Real-World Evidence. Clin Cosmet Investig Dermatol. 2022;15:1649–1658. doi:10.2147/CCID.S364640
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35(7):e15524. doi:10.1111/dth.15524
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Battista T, Marano L, Cacciapuoti S, Potestio L. Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: a 2-Year Real-Life Retrospective Study. J Clin Med. 2023;12:9. doi:10.3390/jcm12093233
   Web of Science ®Google Scholar
• Khatri A, Eckert D, Oberoi R, et al. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis. J Clin Pharmacol. 2019;59(12):1656–1668. doi:10.1002/jcph.1473
   PubMed Web of Science ®Google Scholar
• Lo Y, Chiu HY, Tsai TF. Clinical Features and Genetic Polymorphism in Chinese Patients with Erythrodermic Psoriasis in a Single Dermatologic Clinic. Mol Diagn Ther. 2020;24(1):85–93. doi:10.1007/s40291-019-00441-x
   PubMed Web of Science ®Google Scholar
• Li LF, Sujan SA, Yang H, Wang WH. Serum immunoglobulins in psoriatic erythroderma. Clin Exp Dermatol. 2005;30(2):125–127. doi:10.1111/j.1365-2230.2004.01717.x
   PubMed Web of Science ®Google Scholar
• Zhang P, Chen HX, Duan YQ, et al. Analysis of Th1/Th2 response pattern for erythrodermic psoriasis. J Huazhong Univ Sci Technol Med Sci. 2014;34(4):596–601. doi:10.1007/s11596-014-1322-0
   PubMedGoogle Scholar
• Napolitano M, Fabbrocini G, Genco L, Martora F, Potestio L, Patruno C. Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience. J Eur Acad Dermatol Venereol. 2022;36(9):1497–1498. doi:10.1111/jdv.18137
   PubMed Web of Science ®Google Scholar
• Napolitano M, Maffei M, Patruno C, et al. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis. Dermatol Ther. 2021:e15120. doi:10.1111/dth.15120
   PubMed Web of Science ®Google Scholar
• Patruno C, Potestio L, Scalvenzi M, et al. Dupilumab for the treatment of adult atopic dermatitis in special populations. J Dermatolog Treat. 2022:1–6. doi:10.1080/09546634.2022.2102121
   PubMed Web of Science ®Google Scholar
• Wang H, Wang S, Li L, et al. Involvement of the cytokine TWEAK in the pathogenesis of psoriasis vulgaris, pustular psoriasis, and erythrodermic psoriasis. Cytokine. 2021;138:155391. doi:10.1016/j.cyto.2020.155391
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;1–3. doi:10.1080/14712598.2022.2113872
   Web of Science ®Google Scholar
• Megna M, Potestio L, Battista T, et al. Immune response to Covid-19 mRNA vaccination in psoriasis patients undergoing treatment with biologics. Clin Exp Dermatol. 2022. doi:10.1111/ced.15395
   Web of Science ®Google Scholar
• Potestio L, Villani A, Fabbrocini G, Martora F. Cutaneous reactions following booster dose of COVID-19 mRNA vaccination: what we should know? J Cosmet Dermatol. 2022. doi:10.1111/jocd.15331
   Web of Science ®Google Scholar
• De Lucia M, Potestio L, Costanzo L, Fabbrocini G, Gallo L. Scabies outbreak during COVID-19: an Italian experience. Int J Dermatol. 2021;60(10):1307–1308. doi:10.1111/ijd.15809
   PubMed Web of Science ®Google Scholar
• Marasca C, Annunziata MC, Camela E, et al. Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: new Perspectives and Applications. J Clin Med. 2022;11:6. doi:10.3390/jcm11061511
   Web of Science ®Google Scholar
• Martora F, Villani A, Marasca C, Fabbrocini G, Potestio L. Skin reaction after SARS-CoV-2 vaccines Reply to “cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience”. J Eur Acad Dermatol Venereol. 2023;37(1):e43–e44. doi:10.1111/jdv.18531
   PubMed Web of Science ®Google Scholar
• Stinco G, Errichetti E. Erythrodermic psoriasis: current and future role of biologicals. BioDrugs. 2015;29(2):91–101. doi:10.1007/s40259-015-0119-4
   PubMed Web of Science ®Google Scholar